BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 14743886)

  • 1. Safety of thiopurines in the treatment of inflammatory bowel disease.
    de Jong DJ; Derijks LJ; Naber AH; Hooymans PM; Mulder CJ
    Scand J Gastroenterol Suppl; 2003; (239):69-72. PubMed ID: 14743886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
    Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
    Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
    Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.
    Jansen FM; Smits LJT; Thomas PWA; de Jong DJ; Kreijne JE; van Dop WA; den Broeder N; Hoentjen F
    Dig Dis Sci; 2023 Jul; 68(7):2936-2945. PubMed ID: 37131100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
    Leong RW; Gearry RB; Sparrow MP
    Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients.
    Gilissen LP; Derijks LJ; Bos LP; Verhoeven HM; Bus PJ; Hooymans PM; Engels LG
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):705-10. PubMed ID: 15201586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
    Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
    Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of thiopurine-related adverse events in elderly patients with IBD.
    Calafat M; Mañosa M; Cañete F; Ricart E; Iglesias E; Calvo M; Rodríguez-Moranta F; Taxonera C; Nos P; Mesonero F; Martín-Arranz MD; Mínguez M; Gisbert JP; García-López S; de Francisco R; Gomollón F; Calvet X; Garcia-Planella E; Rivero M; Martínez-Cadilla J; Argüelles F; Arias L; Cimavilla M; Zabana Y; Domènech E;
    Aliment Pharmacol Ther; 2019 Oct; 50(7):780-788. PubMed ID: 31429097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
    Chaparro M; Ordás I; Cabré E; Garcia-Sanchez V; Bastida G; Peñalva M; Gomollón F; García-Planella E; Merino O; Gutiérrez A; Esteve M; Márquez L; Garcia-Sepulcre M; Hinojosa J; Vera I; Muñoz F; Mendoza JL; Cabriada JL; Montoro MA; Barreiro-de Acosta M; Ceña G; Saro C; Aldeguer X; Barrio J; Maté J; Gisbert JP
    Inflamm Bowel Dis; 2013 Jun; 19(7):1404-10. PubMed ID: 23665964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD.
    de Boer NK; van Bodegraven AA; Jharap B; de Graaf P; Mulder CJ
    Nat Clin Pract Gastroenterol Hepatol; 2007 Dec; 4(12):686-94. PubMed ID: 18043678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.
    Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA; Roberts RL; Kennedy MA
    Aliment Pharmacol Ther; 2003 Aug; 18(4):395-400. PubMed ID: 12940924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity profile of thiopurines in inflammatory bowel disease: a retrospective cohort analysis.
    Labidi A; Hafi M; Ben Mustapha N; Serghini M; Fekih M; Boubaker J
    Tunis Med; 2020 May; 98(5):404-412. PubMed ID: 32548844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.